VivoSeq
Oncology

Squamous Cell Carcinoma of Head and Neck

7

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Squamous Cell Carcinoma of Head and Neck is an early-stage landscape with 7 programs across 6 companies. The most active players are Johnson & Johnson Enterprise Innovation Inc., Teva, Johnson & Johnson. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

J

Johnson & Johnson Enterprise Innovation Inc.

1 program

Phase 1Teva logo

Teva

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 3A

Avyxa

1 program

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

4 of 6 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody233%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 86% of 7 pipeline programs.

Analysis

Trial Status

3

clinical trials

Recruiting3 · 100%

Clinical Trials

Trial Activity

A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma
Recruiting·Johnson & Johnson logoJohnson & Johnson·Preclinical·NCT06385080·287 enrolled
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT07276399·500 enrolled
A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Recruiting·JJohnson & Johnson Enterprise Innovation Inc.·Phase 1·NCT07219212·45 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)